ScripSorrento’s Phase II Avertinib Trials Show Potential For At-Risk Patients Sorrento Therapeutics, Inc. ’s abivertinib has shown positive results in two Phase II trials in hospitalized COVID-19 patients
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Collaborates With Artios On DD